Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of THR-1442 (Bexagliflozin) in Healthy Chinese Subjects
NCT05369078Phase 1Unknown
- Sponsor
- Newsoara Biopharma
- Start
- Dec 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Newsoara Biopharma. Primary endpoint: Treatment Emergent Adverse Events. Status: unknown.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05369078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369078.